Skip to content
Menu

Revolution Medicines, Inc. RVMD

Full chart Compare
Set alert

Price alert · RVMD

All alert types
166.87 USD -5.42 (-3.15%)

Regular-session close

166.87 0.00 0.00%

After hours · Nov 16, 6:41 PM ET

165.95 Day range 173.59
67.27 52-week range 224.31
YTD
+109.50%
1 year
+146.30%
Market cap
36.09B
Revenue (ttm)
197.56M
EPS (ttm)
-8.92
Shares out
216.29M
Forward P/E
-52.94
YTD return
+109.50%
1-year return
+146.30%
50-day average
194.46
200-day average
159.88
Enterprise value
34.83B
Volume
2.50M
Avg volume
2.18M
Open
172.00
Previous close
172.29
Day's range
165.95 – 173.59
52-week range
67.27 – 224.31
Beta
1.43
Analysts
Strong Buy
Price target
274.76 (+64.7%)
Earnings date
Feb 24, 2027

5D -29.83 (-15.17%)

170180190200TueWedThuFriMon166.87

Key statistics

Price / sales
182.69
Price / book
15.03
Free cash flow
-886.29M
Total cash
3.65B
Total debt
1.21B
Return on equity
-93.56%
Short % of float
6.38%

Fundamental scorecard

4 of 25 checks passed on RVMD’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
RVMD Revenue — quarterly 197.56M
RVMD Net income — quarterly -407.46M
RVMD EPS — quarterly -1.90

Earnings

RVMD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 2026-1.16———
Nov 4, 2026Sep 30, 2026-2.35-1.90+0.45+19.15%
Aug 5, 2026Jun 30, 2026-2.04-3.06-1.02-50.00%
May 6, 2026Mar 31, 2026-1.84-2.29-0.45-24.46%
Feb 25, 2026Dec 31, 2025-1.58-1.86-0.28-17.72%
Nov 5, 2025Sep 30, 2025-1.42-1.61-0.19-13.38%

Upgrades / downgrades

RVMD analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026HC Wainwright & Co.mainBuyBuy
Nov 5, 2026TD CowenmainBuyBuy
Nov 5, 2026RBC CapitalmainOutperformOutperform
Nov 5, 2026Piper SandlermainOverweightOverweight
Nov 5, 2026Truist SecuritiesreitBuyBuy
Nov 5, 2026GuggenheimmainBuyBuy

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
revmed.com

News

Your note

Sign in to keep a note on RVMD — it syncs with the Stock Master app.

Insider holders

RVMD insider holders
InsiderRelationLatest transactionDateShares held
ANDERS JACK LEEChief Financial OfficerSaleJun 23, 2026123,269
BORISY ALEXISDirectorStock Award(Grant)Jun 17, 20262,340,080
GOLDSMITH MARK AChief Executive OfficerSaleAug 20, 20260
HORN MARGARET AChief Operating OfficerSaleJun 16, 2026154,647
HORNING SANDRADirectorStock Award(Grant)Jun 17, 202697,765
KELSEY STEPHEN MICHAELOfficerSaleSep 10, 2026291,876

Institution ownership

RVMD institution ownership
Holder% heldSharesValueReported
FMR, LLC7.12%15,397,7142.57BSep 29, 2026
Blackrock Inc.6.41%13,857,3242.31BSep 29, 2026
Farallon Capital Management LLC6.27%13,550,7962.26BJun 29, 2026
Baker Bros. Advisors, LP5.29%11,443,3571.91BJun 29, 2026
Jupiter Topco LLC4.96%10,736,1451.79BJun 29, 2026
Darwin Global Management, Ltd.4.91%10,629,8221.77BJun 29, 2026

Fund ownership

RVMD fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.96%6,412,4131.07BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.14%4,631,150772.80MJun 29, 2026
Growth Fund of America1.37%2,964,768494.73MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.23%2,670,853445.69MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.14%2,472,885412.65MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.06%2,291,511382.38MJun 29, 2026